U.S., Oct. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07206095) titled 'Integrative Diagnosis for SCD and Other RADs' on Sept. 16.
Brief Summary: INTEGRA aims at enabling personalized medicine for RHADs patients by the establishment of an integrative diagnostic approach based on deep phenotypic and genetic characterization through combining new generation methodologies.
Study Start Date: Nov. 13, 2020
Study Type: OBSERVATIONAL
Condition:
Sickle Cell Disease
Thalassaemia
Congenital Dyserythropoietic Anemia (CDA)
Enzyme Disorder; Anemia
Spherocytosis, Hereditary
Stomatocytosis
Hemoglobin Disorder
Anemia Due to Membrane Defect
Rare Anemia Disorders
Intervention:
GENETIC: Analysis of genetic modifiers...